Alphatec Holdings, Inc.

Alphatec Holdings, Inc. (ATEC) Market Cap

Alphatec Holdings, Inc. has a market capitalization of $1.61B.

Financials based on reported quarter end 2025-12-31

Price: $10.62

β–² 0.14 (1.34%)

Market Cap: 1.61B

NASDAQ Β· time unavailable

CEO: Patrick S. Miles

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 2006-06-12

Website: https://www.atecspine.com

Alphatec Holdings, Inc. (ATEC) - Company Information

Market Cap: 1.61B Β· Sector: Healthcare

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.

Analyst Sentiment

75%
Strong Buy

Based on 16 ratings

Analyst 1Y Forecast: $23.09

Average target (based on 3 sources)

Consensus Price Target

Low

$20

Median

$25

High

$27

Average

$24

Potential Upside: 128.3%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ ALPHATEC HOLDNGS INC (ATEC) β€” Investment Overview

🧩 Business Model Overview

Alphatec Holdings Inc (ATEC) is a medical device company focused primarily on the development, design, and marketing of innovative solutions for the surgical treatment of spine disorders. ATEC's business model revolves around delivering differentiated procedural solutions that address unmet clinical needs in spine surgery, including degenerative conditions, deformity, trauma, and minimally invasive procedures. The company works closely with surgeons and healthcare providers to develop intuitive products that improve surgical outcomes and address both clinical and economic imperatives within the healthcare system. Its operations are vertically integrated, encompassing research and development (R&D), manufacturing, distribution, and physician education.

πŸ’° Revenue Streams & Monetisation Model

ATEC primarily generates revenue from the sale of spinal implant systems, disposables, biologics, and related surgical instruments. The company's commercial strategy is focused on direct sales to hospitals, ambulatory surgery centers, and spine surgeons, with a growing emphasis on its internal salesforce. Revenues are typically derived from one-time sales of implantable hardware and recurring sales of biologics and disposables used during spinal procedures. Service revenues are also realized via support offerings such as surgical planning software, digital navigation platforms, and intraoperative support. Pricing is influenced by product differentiation, procedural complexity, surgeon preference, and reimbursement trends in the spine surgery market. The company’s expanding product portfolio supports cross-selling opportunities and increased share-of-wallet per procedure.

🧠 Competitive Advantages & Market Positioning

ATEC differentiates itself through its innovation-led portfolio tailored to the evolving demands of spine surgeons. The company maintains a robust pipeline developed via close partnership with key opinion leaders and clinical advisers, allowing for a rapid cadence of both incremental and transformative product launches. Vertical integration of R&D and manufacturing enhances ATEC's ability to iterate quickly and maintain quality control. The company benefits from deep surgeon relationships, supported by specialized training programs and high-touch clinical support, fostering procedural adoption and surgeon loyalty. Its strategy emphasizes procedural solutions rather than commoditized components, seeking to enable better clinical outcomes while capturing higher margins. In a competitive landscape dominated by larger incumbents such as Medtronic and Stryker, ATEC pursues differentiation through procedural specificity, customer service, and rapid innovation cycles.

πŸš€ Multi-Year Growth Drivers

ATEC's growth outlook is supported by several secular and company-specific drivers:
  • Addressable Market Expansion: The global spine surgery market continues to benefit from an aging population, increased prevalence of spinal conditions, and growing patient demand for restorative mobility. Broader indications for surgical treatment and increased adoption of minimally invasive techniques further enlarge ATEC’s addressable opportunities.
  • Innovation and New Product Introductions: ATEC's ongoing cadence of product launches enhances procedural breadth and depth, drives wallet share growth per surgeon, and opens new procedure categories. Proprietary products, advanced spinal navigation, and next-generation biologics expand the platform’s reach.
  • Salesforce Expansion and Channel Maturation: The strengthening and scaling of the company’s dedicated salesforce, with a focus on high-growth geographic markets and deepening surgeon relationships, enables penetration into new accounts and geographies.
  • Operational Leverage: Vertical integration, manufacturing investments, and logistical enhancements support margin expansion and more agile service delivery, amplifying the impact of top-line growth.
  • Platform Solutions and Ecosystem Effects: Efforts to bundle procedural solutions, including enabling technologies and software support, position ATEC to drive recurring revenue and build defensible customer relationships.

⚠ Risk Factors to Monitor

Several risks are inherent to ATEC’s business and must be actively monitored:
  • Regulatory and Reimbursement Risks: Changes in U.S. FDA clearance pathways, clinical data requirements, or payer reimbursement rates could impact product launches, market adoption, or pricing power.
  • Competitive Pressures: The spine surgery market includes large, well-capitalized players capable of aggressive pricing, rapid innovation, and bundled offerings. Displacement by technological advances or clinical preference changes remains possible.
  • Product Liability and Clinical Risks: Medical devices carry inherent risk of adverse events, product recalls, or litigation, potentially leading to financial loss or reputational harm.
  • Customer Concentration and Execution Risk: Overreliance on high-volume surgeons or a narrower hospital customer base could expose ATEC to volatility. Execution challenges in commercial expansion or manufacturing scale-up could also impair growth.
  • Macroeconomic and Supply Chain Headwinds: Broader economic slowdowns, hospital capital budget constraints, and supply chain disruptions can impede procedure volumes and delay product sales.

πŸ“Š Valuation & Market View

ATEC is generally valued within the context of high-growth, innovation-driven medtech companies. The company's valuation framework often incorporates a blend of revenue multiples and forward-looking profitability considerations, as near-term profit remains subordinate to growth investments. Investors typically benchmark ATEC against both established spine peers and a broader set of surgical innovators, considering factors such as revenue growth rates, gross margin progression, commercial execution, and new product adoption curves. The consensus market view recognizes ATEC’s potential for above-market growth, an expanding addressable market, and a favorable innovation pipeline, although with heightened risk due to the company's scale, cash flow profile, and sensitivity to medical technology adoption cycles.

πŸ” Investment Takeaway

Alphatec Holdings stands out as an innovation-driven challenger within the spine surgery ecosystem, offering a procedurally integrated suite of solutions backed by an expanding commercial presence and a dynamic pipeline. The company’s commitment to clinical partnership and agile product development positions it to capture share in a growing, clinically complex market segment. While competitive, regulatory, and execution risks are non-trivial, ATEC’s multi-year potential rests upon continued innovation, commercial scale-up, and realization of operational leverage. For investors seeking exposure to transformative healthcare technologies and growth within orthopedics and spine care, ATEC represents a compelling but higher-risk opportunity demanding careful due diligence and ongoing monitoring.

⚠ AI-generated β€” informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"ATEC reported revenue of $212.9M with a net loss of $21.7M and an EPS of -$0.15 for the most recent quarter. The company generated an operating cash flow of $20.7M and a free cash flow of $9.57M, indicating efficient cash flow management. The balance sheet shows total assets of $791.2M and total liabilities of $755.2M, leaving a thin equity of just $36.0M. With a net debt of $459.1M, leverage is a concern. Despite a slight price appreciation of 12.01% over the last year, ATEC's year-to-date performance is down 43.40%, reflecting significant volatility. The absence of dividends suggests a reinvestment strategy, but shareholder returns from price appreciation alone may be inadequate to attract long-term investment. Price targets range from $16 to $27, averaging a consensus of $23.33, indicating potential upside, though caution is warranted given the operating losses and high leverage."

Revenue Growth

Positive

Revenue of $212.9M indicates solid performance, though growth rate specifics are unprovided.

Profitability

Neutral

A net loss of $21.7M shows challenges in achieving profitability.

Cash Flow Quality

Positive

Positive operating and free cash flow demonstrate effective cash management.

Leverage & Balance Sheet

Caution

High liabilities relative to equity raise concerns about financial stability.

Shareholder Returns

Neutral

12.01% 1-year price change is positive, but overall financial volatility affects score.

Analyst Sentiment & Valuation

Neutral

Price targets suggest potential upside, although significant volatility exists.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management projected β€œvery good things” and durability: Q4 revenue $213M (+20% YoY) and adjusted EBITDA $33M (nearly +400 bps YoY improvement; 16% exit margin), with free cash flow $8M. For 2026, they reaffirm revenue ~$890M (+17%) but raised adjusted EBITDA guidance to $134M (15% margin), alongside a plan for at least $20M free cash flow. The key candid operational hurdle was not a macro/tariff issue but mix and timing: a 120 bps international mix headwind and deformity-driven seasonality changes that β€œmask underlying momentum,” making YoY Q4 growth look lower than Q2/Q3. In Q&A, the pressure came from the market reactionβ€”shares trading offβ€”and an explicit question confirming that EBITDA is the new swing factor (analyst cites ~10% higher than consensus in Q4 and asks what changed in 2026). Management reassured on cadence by anchoring Q1–Q3 seasonality to 2025 percentages (22.1%/24.5%/25.5%) and aligning EBITDA drop-through accordingly.

AI IconGrowth Catalysts

  • Surgeon adoption and procedural volume growth (+21% procedural volume in Q4; net new surgeon users +23%)
  • Lateral leadership supported by integrated ecosystem and disciplined sales-channel expansion
  • Deformity momentum driven by expanding EOS installed base (EOS Edge) and higher adoption of EOS Insight (implant usage within 6 months of EOS Insight adoption growing at almost double the average growth rate)
  • Shift in deformity seasonality smoothing YoY comparisons (Q2/Q3 stronger deformity volumes reduced Q4 YoY growth rate)
  • 2025 technology/software/tooling releases from EOS Insight and proceduralization across more challenging pathologies (PTP applied to more complex cases)

Business Development

  • Exclusive distribution partnership with Theradaptive (expected next BMP on spine market)

AI IconFinancial Highlights

  • Q4 revenue: $213.0M (+20% YoY; +$16.0M sequential); surgical revenue $190.0M (+21% YoY; +7% sequential); EOS revenue $23.0M (+14% YoY)
  • Q4 adjusted EBITDA: $33.0M; +61% YoY; nearly +400 bps improvement vs prior-year period; Q4 exit rate 16% adjusted EBITDA margin
  • Q4 non-GAAP gross margin: 70.5% (flat sequential; +80 bps YoY)
  • U.S. revenue per case: +1.4%; lateral and cervical each +6%, partially offset by cervical mix and a 120 bps international mix headwind (international lower avg revenue per case)
  • Q4 free cash flow: $8.0M (within previously communicated $6.0M–$8.0M range)
  • Full-year 2025 revenue: $764.0M (+25% vs prior year; +$153.0M YoY); full-year surgical revenue $687.0M (+26%); full-year EOS revenue $77.0M (+15%)
  • Full-year non-GAAP gross margin: 70.2% (flat YoY)
  • Full-year non-GAAP R&D: $57.0M (~7% of sales), +140 bps improvement YoY
  • Full-year non-GAAP SG&A: $449.0M (~59% of sales), +790 bps improvement YoY
  • Full-year adjusted EBITDA: $93.0M (~12% of revenue), +$63.0M YoY and +720 bps improvement
  • Full-year free cash flow: $3.0M (first full year of free cash flow)
  • 2026 guidance: revenue ~$890.0M (+17%); adjusted EBITDA $134.0M (increased vs preannounced); implies 15% adjusted EBITDA margin; operating before incremental asset investment $110.0M; expected free cash flow at least $20.0M
  • Analyst pressure acknowledged in Q&A: shares trading off; EBITDA was cited as ~10% higher than consensus in Q4; 2026 revenue guidance unchanged at $890.0M but EBITDA guidance taken up per analyst question/confirmation

AI IconCapital Funding

  • Cash at Q4 end: $161.0M
  • Revolver availability: $60.0M undrawn at quarter end
  • Total cash + available cash: $221.0M
  • Q4 operating cash flow: $21.0M
  • Full-year operating cash flow: $45.0M; investing back into business: $42.0M
  • 2026 cash generation plan: at least $20.0M free cash flow; operating before incremental asset investment $110.0M (after cash interest/EOO and working capital requirements)

AI IconStrategy & Ops

  • Ongoing proceduralization (clinical distinction via procedural approach; PTP applied to more challenging pathologies)
  • EOS Insight expansion and information flow into operating room experience (EOS Insight described as a disruptor/releasing pediatric and cervical tools)
  • Sales force expansion and procedural solutions buildout; investment in long-term growth and scalability
  • Gross margin improvement expected toward ~71% exiting 2026 driven by asset efficiency and cost improvement efforts
  • Operating expense growth guided at ~11% with revenue growth at 17% to drive nearly +400 bps operating margin improvement vs 2025
  • Valence: purpose-built integrated navigation/robotically controlled precision centerpiece for PTP; controlled release throughout 2026; replacement cycle for Stealth referenced

AI IconMarket Outlook

  • 2026 revenue guidance: ~$890.0M
  • 2026 surgical revenue guidance: ~$805.0M (mid-teens volume growth; low single-digit revenue per surgery)
  • 2026 EOS revenue guidance: ~$85.0M
  • 2026 adjusted EBITDA guidance: $134.0M (15% margin) β€” increased vs earlier January preannouncement
  • Q1 2026 revenue cadence (commentary): uses 2025 seasonality as baseline; Q1 2025 was 22.1% of sales, Q2 24.5%, Q3 25.5%; Q1 2026 expected to respect these starting points
  • Q1 2026 EBITDA pattern (commentary): likely more drop-through in Q1 and slightly lower than average in the rest of the year to reach 32% overall (as stated by management)

AI IconRisks & Headwinds

  • International business mix headwind: 120 bps headwind due to lower avg revenue per case vs U.S. (Q4 U.S. revenue per case up 1.4% with lateral/cervical up 6% partially offset by mix)
  • Deformity seasonality shifting (could mask underlying momentum; management said deceleration appearance is masking momentum and reduced Q4 YoY growth)
  • Analyst skepticism / stock reaction risk implied by Q&A (shares trading off; investors questioning moving parts despite revenue guidance being in line)

Sentiment: MIXED

Note: This summary was synthesized by AI from the ATEC Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (ATEC)

Β© 2026 Stock Market Info β€” Alphatec Holdings, Inc. (ATEC) Financial Profile